To the Editor: Kefford’s contention that making cancer drugs affordable requires coherent policy and cannot be left to market forces1 is correct.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Kefford RF. Drug treatment for melanoma: progress, but who pays? Med J Aust 2012; 197: 198-199. <MJA full text>
- 2. Pronovost PJ, et al. How can clinicians measure safety and quality in acute care? Lancet 2004; 363: 1061-1067.
- 3. Bruera E, Yennurajalingam S. Palliative care in advanced cancer patients: how and when? Oncologist 2012; 17: 267-73.
- 4. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742.
- 5. Palliative Care Australia. National Palliative Care Consensus Statement: a call to action. Canberra: PCA, 2011. http://www.palliativecare.org.au/Portals/46/PAL31612%20consensus%20 statement_newer%20style%203%20(2).pdf (accessed Oct 2012).
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.